Annals of Neurology · 1992 · 31 citations · 17 references
MedicineNeurologyNeuroscienceNeurochemistryNeuropharmacologyNeuropsychiatryBasal GangliaDopaminergic PharmacologyNeurodegenerative DiseasesNeurodegenerative DisordersNeurotransmissionParkinsonian DisordersD1-like Dopamine ReceptorsD2-like Dopamine ReceptorsDisorderDopamine D1-like ReceptorsDopamine D2-like ReceptorsDopamine Receptor AgonistsDopamine Receptor SubtypesReceptors
Dopamine D1 and D2 receptors were studied in brain tissue sections from a typical patient with progressive supranuclear palsy and in 7 age-matched brains. The density of D1 receptors in the caudate-putamen and frontal cortex of the patient was within control limits. By contrast, the density of nigral D1 receptors and striatal D2 receptors was dramatically reduced in the patient as compared to the control brains. This work shows again that the loss of striatal D2 receptors is the most plausible explanation for the poor response to dopaminergic drugs in patients with progressive supranuclear palsy. While the loss of nigral D1 receptors can be explained by the loss of nigral neurons, it seems that neurons bearing striatal D1 receptors are spared in progressive supranuclear palsy. The clinical effects of selective D1 agonists are worth testing in this devastating disorder.
17
Progressive Supranuclear Palsy
John C. Steele · Archives of Neurology · 1964 · 1.9K citations
Handbook of clinical neurology
Zd. Servit · Electroencephalography and Clinical Neurophysiology · 1975 · 1.7K citations
Dopamine receptors in human brain: Autoradiographic distribution of D2 sites
Montserrat Camps, Roser Cortés, B. Gueye et al. · Neuroscience · 1989 · 309 citations
Dopaminergic and cholinergic lesions in progressive supranuclear palsy
Merle Ruberg, France Javoy‐Agid, Étienne C. Hirsch et al. · Annals of Neurology · 1985 · 221 citations